Computational studies of target-specific radiopharmaceuticals for theranostics

Silvia Gervasoni1, Camilla Guccione1, Giuliano Malloci1

  • 1Department of Physics, University of Cagliari, Cittadella Universitaria, S.P. Monserrato-Sestu Km 0.7, Monserrato, I-09042, CA, Italy.

Insights

Computational methods accelerate the development of radiopharmaceuticals for nuclear medicine imaging and therapy. These techniques optimize drug design for targets like receptors, enzymes, and transporters, paving the way for advanced theranostic agents.

Area of Science:

  • Nuclear medicine
  • Computational chemistry
  • Drug discovery

Background:

  • Radiopharmaceuticals are crucial for diagnostic imaging and targeted therapy in nuclear medicine.
  • Computational techniques like molecular docking and dynamics are increasingly integrated into drug discovery.
  • These methods aid in developing novel radiopharmaceutical compounds for various diseases.

Purpose of the Study:

  • To review recent computational studies on radiopharmaceuticals targeting receptors, enzymes, and transporters.
  • To highlight the role of advanced computational methods in understanding radiopharmaceutical interactions.
  • To emphasize the potential of computational approaches for designing next-generation theranostic agents.

Main Methods:

  • Molecular docking and molecular dynamics simulations.
  • In silico investigations of radiopharmaceutical interactions with enzymes.
  • Quantum mechanics calculations and free energy estimations.

Main Results:

  • Molecular simulations optimized ligand binding for receptors like chemokine receptor 4 and neurokinin-1.
  • In silico studies explored radiopharmaceutical inhibitors for enzymes such as prostate-specific membrane antigen.
  • Computational approaches enhanced understanding of radiopharmaceutical binding modes and stability.

Conclusions:

  • Computational methods offer a cost-effective pathway for designing advanced radiopharmaceuticals.
  • Molecular databases and AI-driven design are vital for future radiopharmaceutical development.
  • These approaches are essential for creating next-generation theranostic agents for cancer and neurological disorders.

Related Concept Videos